Semaglutide for Opioid Use Disorder
Treatments studied
Part of Mental health clinical trials.
This study tests whether a once-weekly injection of semaglutide (a GLP-1 receptor agonist) can reduce opioid use in people who are already on buprenorphine or methadone but still using opioids. It lasts about 19 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with moderate to severe opioid use disorder and are in outpatient treatment
- You have been on buprenorphine for at least 2 weeks or methadone for at least 4 weeks and still have had opioid use
- You are not pregnant, breastfeeding, or planning pregnancy and agree to use birth control if needed
- You do not have certain medical conditions like type 1 diabetes, severe heart disease, pancreatitis, thyroid cancer, or kidney failure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether semaglutide (a medication used for weight management) can help people on buprenorphine or methadone reduce their opioid use. If it works, it could provide additional support during recovery.
This trial tests if semaglutide (a medicine used for diabetes and weight loss) can help reduce methamphetamine use. If you qualify, you might get the study drug and support to help you cut back or stop using methamphetamine.
This study tests a medication called semaglutide (a once-weekly injection) to help people with obesity lose weight. It is for adults who have already tried lifestyle changes without success.
This study tests whether semaglutide, a medication used for weight management, can help reduce cocaine use in people with cocaine use disorder. You may qualify if you have a body mass index (BMI) of 25 or higher and recently used cocaine.
This study tests whether a low dose of semaglutide (a once-weekly injection) can help obese adults without diabetes lose weight. Semaglutide works by reducing appetite and helping your body use food differently.
This study tests whether a weekly injection of semaglutide (a medication used for weight loss and diabetes) can help reduce symptoms of depression in people who have major depressive disorder and are overweight or obese.
Hear when a new Opioid Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.